Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, comments on clinical trials of votobatinib in patients with CML, most of whom have received 3 or more TKIs previously. Results suggest about 60% of patients respond to votobatinib with a good safety profile, although Dr Cortes cautions that the drug is not effective in patients with T315I mutations.